Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Marker Therapeutics Inc’s stock clocked out at $2.86, down -4.03% from its previous closing price of $2.98. In other words, the price has decreased by -$4.03 from its previous closing price. On the day, 64762.0 shares were traded. MRKR stock price reached its highest trading level at $3.0629 during the session, while it also had its lowest trading level at $2.75.
Ratios:
To gain a deeper understanding of MRKR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.15 and its Current Ratio is at 3.15. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on March 25, 2021, initiated with a Overweight rating and assigned the stock a target price of $6.
On March 19, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $6.
Piper Sandler Downgraded its Overweight to Neutral on May 12, 2020, whereas the target price for the stock was revised from $5 to $2.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 23 ’24 when ELMS STEVE bought 11,085 shares for $3.20 per share. The transaction valued at 35,472 led to the insider holds 325,370 shares of the business.
New Enterprise Associates 16, bought 554,250 shares of MRKR for $1,773,600 on Dec 23 ’24. The 10% Owner now owns 1,625,678 shares after completing the transaction at $3.20 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRKR now has a Market Capitalization of 30622876 and an Enterprise Value of 19592210. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.67 while its Price-to-Book (P/B) ratio in mrq is 3.42. Its current Enterprise Value per Revenue stands at 5.256.
Stock Price History:
The Beta on a monthly basis for MRKR is 1.48, which has changed by -0.4004193 over the last 52 weeks, in comparison to a change of 0.23806548 over the same period for the S&P500. Over the past 52 weeks, MRKR has reached a high of $5.99, while it has fallen to a 52-week low of $2.44. The 50-Day Moving Average of the stock is -20.57%, while the 200-Day Moving Average is calculated to be -26.72%.
Shares Statistics:
It appears that MRKR traded 59.91K shares on average per day over the past three months and 51400 shares per day over the past ten days. A total of 8.90M shares are outstanding, with a floating share count of 7.06M. Insiders hold about 34.06% of the company’s shares, while institutions hold 8.95% stake in the company. Shares short for MRKR as of 1730332800 were 69997 with a Short Ratio of 1.40, compared to 1727654400 on 55784. Therefore, it implies a Short% of Shares Outstanding of 69997 and a Short% of Float of 1.09.
Earnings Estimates
Current recommendations for the stock of the company come from 1 analysts. The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.32 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$1.05 and -$1.05 for the fiscal current year, implying an average EPS of -$1.05. EPS for the following year is -$2.19, with 1.0 analysts recommending between -$2.19 and -$2.19.
Revenue Estimates
For the next quarter, 1 analysts are estimating revenue of $1M. There is a high estimate of $1M for the next quarter, whereas the lowest estimate is $1M.
Based on 1 analysts’ estimates, the company’s revenue will be $4M in the next fiscal year. The high estimate is $4M and the low estimate is $4M.
